Kornimate/medical-research-clean huggingface dataset:
association of multiple genetic polymorphisms with clozapine-associated metabolic change in schizophrenia

Conditions: Schizophrenia; Metabolic Syndrome; Genetic Polymorphism

Summary: we are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.

the use of antipsychotics, especially clozapine and olanzapine is associated with metabolic side effects, which put patients with schizophrenia at risk for cardiovascular morbidity or diabetes. the prevalence of the metabolic syndrome was 53.8% of patients who taking clozapine. the high interindividual variability in antipsychotic-induced metabolic abnormalities suggests that genetic makeup is a possible determinant. the genotypes of the multiple gene such as htr2c, lep, adrenergic receptor,ppar,gnb3 are suggested to have associations with the metabolic side effects (weight,glucose,lipid,bp,metabolic syndrome) in patients using antipsychotics. we are going to investigate whether those multiple genetic polymorphisms are associated with the metabolic side effects in patients taking clozapine.

Eligibility criteria:
inclusion criteria: * age 18-65 * who can understand and sign the informed consent exclusion criteria: * who refuse to participate this study

Keywords: schizophrenia metabolic side effect clozapine genetic polymorphism
endoscopic submucosal dissection for early gi neoplasia in the united kingdom

Conditions: Endoscopic Submucosal Dissection

Summary: multicentre cohort study on the use of endoscopic submucosal dissection for the treatment of early gastrointestinal neoplasia.

data will be collected from participating centres on en bloc resection, curative resection, r0 resection and complications/adverse events over a 2 year follow up period. demographic details on the patients included in the study will be captured alongside details on the size and location of their early gastrointestinal dysplastic/neoplastic lesions.

Eligibility criteria:
inclusion criteria: * male or female, aged 18 years or above undergoing endoscopic submucosal dissection * participant is able to give informed consent for participation in the study exclusion criteria: * patients under the age of 18 * patients unable to give informed consent

Keywords: endoscopic submucosal dissection
leucine supplementation and skeletal muscle disuse

Conditions: Disuse Atrophy

Summary: leucine supplementation is widely known for promoting strong influence on skeletal muscle remodeling. this study aims to evaluate the effect of leucine supplementation on disuse-induced skeletal muscle atrophy.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of anterior cruciate ligament injury * physically active * must be able to swallow tablets * non-smokers * do not use nutritional supplements exclusion criteria: * post-surgical complications

Keywords: leucine skeletal muscle disuse atrophy proteolysis
effects of standing and light-intensity activity on ambulatory blood pressure and blood glucose

Conditions: Diabetes; Hypertension; Sleep

Summary: this study aims to test the short-term effects of intermittent standing, slow cycling and slow walking, compared to sitting, on continuous blood glucose and ambulatory blood pressure among pre-hypertensive and pre-diabetic adults.

this study will enroll 10 adults who will each complete four experimental conditions in random order. each of the four experimental conditions are as follows: 1) sit continuously for 8 hours in a simulated office environment, 2) break-up sitting time with standing based on set hourly intervals, 3) break-up sitting time with slow-walking on a treadmill desk based on set hourly intervals, 4) increase energy expenditure by slow cycling based on set hourly intervals. participants will completed each condition one week apart and dietary intake will be standardized by giving participants the same meals during each intervention condition. study measures will include: anthropometrics (height and weight), blood pressure, fasting glucose, 24-continuous glucose monitoring, full-day ambulatory blood pressure monitoring, cognitive testing (cognitive performance), energy expenditure, physical activity via accelerometer, sleep via accelerometer, and heart rate.

Eligibility criteria:
inclusion criteria: * pre-hypertensive (systolic blood pressure 120-139 mmhg, or diastolic blood pressure 80-89 mmhg) * impaired fasting glucose (5.6-6.9 mmil/l) * not meeting the physical activity guidelines for adults (\>=150 min/wk of moderate-to-vigorous physical activity) exclusion criteria: * smoking, pregnancy, known coronary heart disease, orthopedic limitations for performing physical activity, taking medications to control high blood pressure or high blood glucose, special dietary requirements, and being advised by a doctor to avoid prolonged periods of sitting.
opioid-sparing and pain-reducing properties of syntocinon: a dose-effect determination

Conditions: Pain

Summary: some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. in a 6-session laboratory study, the investigators will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, decision-making, and activation of different neural substrates.

the overall project goals are to determine oxytocin effects on oxycodone's subject-rated abuse liability, experimental pain, and to describe the neurobehavioral mechanisms underlying interindividual differences in these effects. generally healthy individuals (determined via medical history review and a screening session) will, after informed consent, self-administer intranasal oxytocin (or placebo, containing the same ingredients but no oxytocin) shortly after oral oxycodone or placebo in a non-residential, double-blind, randomized, placebo-controlled, within-subjects laboratory study. prescreening will assure mri eligibility and drug application safety and, using a validated, comprehensive pain history interview, determine previous or existing chronic pain conditions, including current pain medication use.

Eligibility criteria:
inclusion criteria: * individuals fluent in english will participate. * must report recreational use of opioids. * be within 20% of their ideal body weight. * are not currently experiencing chronic pain (pain on most days during the past 3 months) * have a systolic blood pressure of \<=140 and diastolic blood pressure of \<= 90, and a heart rate \<= 90 beats per minute. * participants must also have a normal electrocardiogram (ekg) reading and bloodwork indicating no major health contraindications. exclusion criteria: * significant current physical disease or major psychiatric disorder. * no self-reported current interest in drug abuse treatment. * women who are pregnant or nursing. * any comorbid illicit substance use disorders or current clinically significant withdrawal for any abused drug excluding nicotine and caffeine. * any conditions that preclude safety in the mri scanner, such as: implanted electrical devices (e.g., cardiac pacemaker, neurostimulator); implanted metallic clips or pins (e.g., aneurysm clip); a history of working with metal (unless able to demonstrate participant is mri safe), and claustrophobia.
study evaluating efficacy and tolerability of veliparib in combination with temozolomide (tmz) or in combination with carboplatin and paclitaxel versus placebo in participants with breast cancer gene (brca)1 and brca2 mutation and metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: the primary objective of the study is to assess the progression-free survival (pfs) of oral veliparib in combination with tmz or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in subjects with brca1 or brca2 mutation and locally recurrent or metastatic breast cancer.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic. * locally recurrent disease must not be amenable to surgical resection or radiation with curative intent. * must have a documented deleterious breast cancer gene brca1 or brca2 germline mutation. * if human epidermal growth factor receptor (her2) positive, subjects must have received and progressed on at least one prior standard her2 directed therapy or the subject must be ineligible to receive anti-her2 therapy. * measurable or non-measurable (but radiologically evaluable) disease by recist (response evaluation criteria in solid tumors) criteria 1.1. * eastern cooperative oncology group (ecog) performance score of 0-2. * subject must have adequate bone marrow, renal and hepatic function. * subject must not be pregnant or plan to conceive a child. exclusion criteria: * received anticancer agent(s) or an investigational agent within 21 days prior to c1d1, or radiotherapy within 28 days prior cycle 1 day 1. * more than 2 prior lines of cytotoxic chemotherapy. * prior treatment of breast cancer with temozolomide, a platinum agent, or a poly (adp ribose) polymerase (parp) inhibitor. * prior taxane therapy for metastatic breast cancer. * a history of or evidence of brain metastases or leptomeningeal disease. * a history of uncontrolled seizure disorder. * pre-existing neuropathy from any cause in excess of grade 1. * known history of allergic reaction to cremophor/paclitaxel. * clinical significant uncontrolled conditions, active infection, myocardial infarction, stroke, or transient ischemic attack, psychiatric illness/social situations that would limit compliance. * pregnant or breastfeeding.

Keywords: parp tmz temodal carboplatin veliparib brca2 mutation carrier breast cancer metastatic breast cancer temozolomide brca1 mutation carrier abt-888 paclitaxel recurrent breast cancer temodar locally recurrent
fluoroscopy vs. computed tomography for diagnosis of displacement and instability of acute scaphoid waist fractures

Conditions: Acute Scaphoid Waist Fractures

Summary: aim: the aim of this study is to analyze if fluoroscopy is as accurate as computed tomography in diagnosing displacement of acute scaphoid waist fractures. primary null hypothesis: fluoroscopy has comparable sensitivity, specificity, accuracy, positive and negative predictive values compared with computed tomography for the diagnosis of displacement of acute scaphoid waist fractures. secondary null hypothesis: all fractures diagnosed as non-displaced and treated without surgery are healed on radiographs and discharged from care within 6 months of injury.

the only confirmed risk factor for nonunion of a scaphoid waist fracture is displacement. there is consensus that displaced fractures should be treated with open or arthroscopically assisted reduction and internal fixation (orif). however, the optimal method to diagnose displacement is debated. radiographic, computed tomography (ct), and arthroscopic diagnostic criteria for the diagnosis of displacement exist. there is no consensus regarding the imaging modality and measurements to use to diagnose scaphoid displacement. the definition of displacement in recent randomized trials is incompletely described and inconsistent. fluoroscopy is more convenient, less expensive, and uses less radiation than ct scanning. if displaced fractures are unstable, then this should be apparent on fluoroscopy. the aim of this study is to analyze if fluoroscopy is as accurate as computed tomography in diagnosing displacement of acute scaphoid waist fractures.

Eligibility criteria:
inclusion criteria: * all patients (\>18 years) with a radiographically visible acute (\< 2 weeks since injury) scaphoid waist fracture will be included. the subject has to speak and write english or spanish fluently to be able to provide informed consent exclusion criteria: * pregnant women * women who are capable of becoming pregnant and not on birth control will be excluded due to the risk of pregnancy.
integrative proteomic characterization of pancreatic ductal adenocarcinoma

Conditions: Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics

Summary: a large-scale, high-throughput, multi-dimensional comprehensive study of pdac multiomics will be carried out. in this study, clinical specimens of resected pdac collected by our research group from 2017 to 2019 will be selected as research objects.tumor tissues and their adjacent non-tumor tissues from more than 200 pdac patients are expected to be used for genome, transcriptome sequencing and mass spectrometry analysis of proteome and phosphorylated proteome.combined with the data results of multiomics, bioinformatics analysis and network database information, we will clarify the relationship between multiomics of pancreatic cancer and established the new subtyping of pancreatic cancer proteome. a molecular landscape of the progression of pancreatic cancer at the genome-transcriptome-proteome level provides new therapeutic targets to improve the prognosis of this deadly disease.


Eligibility criteria:
inclusion criteria: 1. the diagnosis of pancreatic cancer was confirmed by histological examination or fine needle aspiration cytology; 2. the tumor was graded according to the who standard, and the tumor stage was graded according to the tnm stage; exclusion criteria: 1. the inclusion criteria of the above groups were not met; 2. there are few tissue specimens, only enough for clinical diagnosis; 3. patients are unwilling to conduct follow-up study; 4. for the new diagnosed patient, radiotherapy or chemotherapy have been given in the previous three months;
donafenib combined with hepatic artery chemoembolization for perioperative treatment of liver transplantation

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to evaluate the safety and efficacy of the combination of donafenib and tace in the perioperative period of liver transplantation.

this study plans to enroll about 20 patients with hepatocellular carcinoma (hcc) who do not meet the ucsf standard, they will receive donafenib combined with tace in downstaging period and donafenib only in adjuvant period. before the liver transplantation, the safety and efficacy will be evaluated every 3 and 6 weeks, respectively, until liver transplantation or the disease progression that couldn't be treated by tace. after transplantation, the safety and efficacy will be evaluated every 6 and 12 weeks, respectively, until intolerable toxicity, recurrence or up to 12 months treatment.

Eligibility criteria:
inclusion criteria: 1. diagnosis of hcc either by biopsy or according to aasld criteria; 2. at least one measurable lesion according to mrecist; 3. the previous palliative tace treatment did not exceed one time, with an interval of ≥ 6 months; for patients who had received one prior tace treatment, the treated lession progressed or lipiodol deposition was less than 50%; 4. child-pugh class ≤ 7; 5. ecog performance status 0-1; 6. intrahepatic tumors meet any of the following conditions: * beyond the ucsf standard, no more than 5 intrahepatic tumors with the longest diameters ≤ 10cm, no tumor thrombus in the main portal vein * meet the ucsf standard, but afp \> 1000 ng / ml exclusion criteria: 1. the pathological diagnosis was hepatocellular carcinoma intrahepatic cholangiocarcinoma (hcc-icc) mixed type or fibrous lamellar hepatocellular carcinoma; 2. there were inferior vena cava cancer thrombus, hepatic vein cancer thrombus, regional lymph node invasion or extrahepatic metastasis; 3. hcc recurred within 2 years after radical resection or ablation; 4. patients who have received prior liver transplantation, ≥ 2 times of palliative tace or other palliative local treatment (including haic, radiotherapy, etc.), but who have received prior radical hepatectomy, radical ablation and preventive tace for the purpose of anti-recurrence can be enrolled; 5. prior or ongoing systemic therapy (including systemic therapeutic drugs under research, excluding antiviral therapy), including but not limited to tki such as sorafenib, lenvatinib, regofinib, apatinib, and ambrotinib, pd-1 / pd-l1 monoclonal antibody or immunotherapy against pd-1 / pd-l1, etc; 6. there are contraindications to tace determined by the investigators (e.g., portal vein trunk obstruction without formation of collateral vessels, etc.);
design and evaluation of an in-vehicle real-time drunk driving detection system

Conditions: Drunk Driving; Alcohol Drinking; Impaired Driving

Summary: to analyze driving behavior of individuals under the influence of alcohol while driving in a real car. based on the in-vehicle variables, the investigators aim at establishing algorithms capable of discriminating sober and drunk driving using machine learning.

driving under the influence of alcohol (or "drunk driving") is one of the most significant causes of traffic accidents. alcohol consumption impairs neurocognitive and psychomotor function and has been shown to be associated with an increased risk of driving accidents. however, autonomous driving (level 4 or 5) is likely to be broadly available only at a substantially later time point than previously thought due to increasing concerns of safety associated with this technology. therefore, solutions bridging the upcoming time period by more rapidly and directly addressing the problem of drunk driving associated traffic incidents are urgently needed. on the supposition that driving behavior differs significantly between sober state and drunk state, the investigators assume that different driving patterns of people under alcohol influence compared to sober states can be used to generate drunk driving detection models using machine learning algorithms. in this study, driving for data collection is initially performed at a sober baseline state (no alcohol) and then after alcohol administration (with a target of 0.15 mg/l and 0.35 mg/l breath alcohol concentration).

Eligibility criteria:
inclusion criteria: * informed consent as documented by signature. * in possession of a definite swiss or eu driving license. * at least 21 years old * active driving in the last 6 months. * no special equipment needed when driving. * drinks alcohol at least occasionally (moderate/social consumption). * fluent in (swiss) german and no speech impairment. exclusion criteria: * health concerns that are incompatible with alcohol consumption. * any potential participant currently taking illegal drugs or medications that interact with alcohol. * women who are pregnant or breast feeding. * intention to become pregnant during the course of the study. * teetotallers (alcohol abstinent persons). * alcohol misuse (excessive alcohol consumption habits/risky drinking behaviour (according to who definition) and/or the biomarker peth in capillary blood \> 200 ng/ml at first visit. * known or suspected drug abuse within 4 weeks before the study (e.g., positive urine drug test at first visit). * non-compliance to alcohol abstinence within 24 hours before the study visits. * inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant. * participation in another study with investigational drug within the 30 days preceding and during the present study.

Keywords: driving automotive technology car alcohol biomarker test track
well-arm exercise in distal radius fractures

Conditions: Distal Radius Fracture

Summary: a single center randomized control study. patients \>18 years with isolated distal radius fractures treated non-operatively will be randomly assigned to either the treatment group (exercise of contralateral "well" arm) or control group (standard fracture care and rehabilitation).

distal radius fractures are common injuries, especially in the aging population. fracture healing requires immobilization of the injury, which inevitably leads to muscle atrophy and joint stiffness. this strength lost during immobilization can be problematic in patients who are already de-conditioned at baseline. previous research using healthy participants found that exercising a non-immobilized, "well", arm helped attenuate muscle atrophy in the contralateral immobilized arm. the study aims to answer the following questions: does exercise of the contralateral arm prevent muscle atrophy and weakness of the injured arm? does exercise of the contralateral arm improve pain scores in the injured arm

Eligibility criteria:
inclusion criteria: * adults \>18 years with an isolated distal radius fracture treated non-operatively exclusion criteria: * operative treatment, additional injures, previous injury to same arm, neuropathy or neuromuscular disease, dementia

Keywords: distal radius fracture cross-education immobilization
a study to evaluate the benefits of using a range of wound care products from a single manufacturer

Conditions: Wound - in Medical Care

Summary: this study is designed to investigate whether the adoption of the use of a range of wound care products from a single manufacturer makes training in appropriate product selection more effective and results in more accurate selection of the appropriate product for the wound and for the patient's lifestyle, thereby incurring less waste and reducing the number of referrals by the community nursing team to the tissue viability team. one community nursing team will switch to using a full range of dressings and compression products from bsn medical uk for three months. nurse training on the products will be given and nurse competencies and confidence in woundcare and appropriate product selection will be tested at the start and end of the study. the number and type of referrals to the tissue viability team will be measured. total anonymised data on numbers of referrals, wound closure, numbers of wounds and quantity and cost of products used will be collected and compared with the historical record for three months prior to the study. patients will complete a quality of life questionnaire at enrolment and exit from the study. patients for whom bsn medical uk products are not appropriate or not desired by the patient will not be enrolled and will receive the usual range of products available to the community nursing team.


Eligibility criteria:
all healthcare professionals of the billericay team responsible for dressing changes who are willing to take part in this study and give their written informed consent. inclusion criteria for the patients: * patients giving their informed consent and with an open wound being treated by the community nursing team * all patients whose wounds can be treated with bsn medical uk product range for wound and leg ulcer management. exclusion criteria for the patients: * age \<18 years * subjects who do not give their consent for any reason * subjects who are unable to read and understand patient information sheet and consent form

Keywords: woundcare community nursing competence